PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Grallert, H. ; Marzi, C. ; Hauck, S.M. ; Gieger, C.

Omics: Potential role in early-phase drug development.

In: Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. London: Springer, 2015. 189-222
DOI
The development of high-throughput omics technologies has nourished the hope to improve our understanding and treatment of the pathophysiology of globally increasing diseases such as type 2 diabetes and obesity. These technologies provide innovative tools that have the potential to truly revolutionize patient care. Technologies continue to propel the omics fields forward. However, translating research discovery into routine clinical applications use is a complex process not only from scientific prospective but also from ethical, political, and logistic points of view. Particularly the implementation of omics-based tests requires changes in fundamental processes of regulation, reimbursement, and clinical practice. Altogether, developments in the field of omics technologies hold great promise to optimize patient care and improve outcomes and eventually lead to new tests that are well integrated in routine medical care.
Scopus
Cited By
Altmetric
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Sammelbandbeitrag/Buchkapitel
Herausgeber Krentz, A.J.* ; Heinemann, L.* ; Hompesch, M.*
Schlagwörter Genomics; Epigenomics; Transcriptomics; Proteomics; Metabolomics; Microarray; Sequencing; Disease prediction; Pharmacogenomics; Personalized medicine
Sprache englisch
Veröffentlichungsjahr 2015
HGF-Berichtsjahr 2015
e-ISSN 978-1-4471-4920-0
ISBN 978-1-4471-4919-4
Bandtitel Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development
Quellenangaben Band: , Heft: , Seiten: 189-222 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort London
Institut(e) Institute of Epidemiology (EPI)
CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s) 30202 - Environmental Health
30203 - Molecular Targets and Therapies
90000 - German Center for Diabetes Research
Forschungsfeld(er) Genetics and Epidemiology
Enabling and Novel Technologies
PSP-Element(e) G-504091-002
G-504091-004
G-505700-001
G-501900-402
DOI 10.1007/978-1-4471-4920-0_8
Scopus ID 84948807666
Erfassungsdatum 2015-11-18
[➜Korrektur melden]